HER2-Positive Breast Cancer Epidemiology Analysis and Forecast to 2033
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
HER2+/HR+ Breast Cancer Report Overview
In the 8MM, there were 107,352 diagnosed incident cases of invasive HER2+/HR+ breast cancer in 2023. The diagnosed incident cases of invasive HER2+/HR+ breast cancer will register an AGR of more than 1% during 2023-2033.
HER2+/HR+ Breast Cancer Market Outlook, 2023-2033 (Diagnosed Incident Cases)
Buy the Full Report for More Insights into the HER2+/HR+ Breast Cancer Market Forecast
The HER2+/HR+ breast cancer market research report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for HER2+ breast cancer in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China). The report includes a 10-year epidemiology forecast for the diagnosed incident cases of all invasive breast cancer, diagnosed incident cases of HER2+ breast cancer, and five-year diagnosed prevalent cases of HER2+ breast cancer.
Market Size (2022) | 107,352 Cases |
AGR (2023-2033) | >1% |
Forecast Period | 2023 – 2032 |
Key Countries | · Urban China
· The US · France · Germany · Spain · Italy |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
HER2+/HR+ Breast Cancer Market Segmentation by Country
The key countries across the 8MM are Urban China, the US, France, Germany, Spain, Italy, the UK, and Japan among others. In 2023, urban China had the highest number of diagnosed incident cases of invasive HER2+/HR+ breast cancer in the 8MM.
`HER2+/HR+ Breast Cancer Market Analysis by Country, 2023 (%)
Buy the Full Report for More Country Insights into the HER2+/HR+ Breast Cancer Market
Segments Covered in the Report
HER2+/HR+ Breast Cancer Market Country Outlook (Diagnosed Incident Cases)
- Urban China
- The US
- France
- Germany
- Spain
- Italy
- The UK
- Japan
Scope
- This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for HER2+ breast cancer in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China).
- The report includes a 10-year epidemiology forecast for the diagnosed incident cases of all invasive breast cancer, diagnosed incident cases of HER2+ breast cancer, and five-year diagnosed prevalent cases of HER2+ breast cancer.
- The diagnosed incident cases of all invasive breast cancer among women are segmented by age (18 years and older), and by HER2+ status (HER2+/HR+ and HER2+/HR-).
- The diagnosed incident cases of invasive HER2+ breast cancer among women are segmented by stage at diagnosis (stage I–II, stage III, and stage IV), by menopausal status (premenopausal and postmenopausal), by metastatic disease (brain/central nervous system [CNS] metastasis), and by mutations and biomarkers (HLA-A*02 positive, Ki67 expression, MSI/dMMR positive, NTRK expression, PD-L1 expression, RET rearrangements, and TMB-H positive).
- Five-year diagnosed prevalent cases of invasive HER2+ breast cancer are segmented by stage (stage I–II, stage III, and stage IV), and by mutations and biomarkers (HLA-A*02 positive, Ki67 expression, MSI/dMMR positive, NTRK expression, PD-L1 expression, RET rearrangements, and TMB-H positive).
- This epidemiology forecast for HER2+ breast cancer is supported by data obtained from country-specific oncology databases, peer-reviewed articles, and population-based studies.
- The forecast methodology was kept consistent across the 8MM to allow for a meaningful comparison of the forecast diagnosed incident and diagnosed prevalent cases of breast cancer across these markets.
- The epidemiology model accompanying this report also includes diagnosed incident cases of all invasive breast cancer among men and diagnosed incident cases of invasive breast cancer in men by HER2+ status (HER2+/HR+, and HER2+/HR-).
Key Highlights
- Breast cancer is the second most common cancer in the world and the most common cancer in women worldwide, accounting for 25.2% of all incident cases of female cancers, making the disease exceedingly prevalent. Breast cancer is classified based on human epidermal growth factor receptor 2 (HER2) and hormone receptor (HR) status (American Cancer Society, 2019). HER2-/HR+ and HER2-/HR- were analyzed in the HER2-negative breast cancer report. This report explores HER2-positive breast cancer, namely, HER2+/HR+ and HER2+/HR- breast cancer.
- GlobalData epidemiologists used age- and sex-specific diagnosed incidence and prevalence rates to forecast the diagnosed incident and prevalent cases, taking into account the significant relationship between age and HER2-positive breast cancer. GlobalData epidemiologists applied country-specific incidence rates of HER2-positive breast cancer wherever available, to each country’s population to obtain the number of estimated diagnosed incident cases.
- The following data describes epidemiology of HER2+/HR+ and HER2+/HR- cases. In 2020, the 8MM had 97,308 diagnosed incident cases of HER2/HR+ breast cancer. This is expected to increase to 113,608 diagnosed incident cases by 2030, at an Annual Growth Rate (AGR) of 1.68%. In the 8MM, the diagnosed incident cases of HER2+/HR- breast cancer will increase from 53,824 cases in 2020 to 63,106 cases in 2030, at an AGR of 1.72%. This increase is partly attributed to the moderately rising trend in historical incidence in the 8MM, combined with underlying demographic changes in the respective markets. The early diagnosis and development of more effective therapies would improve survival from HER2-positive breast cancer.
Reasons to Buy
- The HER2-Positive Breast Cancer epidemiology series will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global MM market.
- Quantify patient populations in the global HER2-Positive Breast Cancer market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups that present the best opportunities for HER2-Positive Breast Cancer therapeutics in each of the markets covered.
Table of Contents
Table
Figures
Frequently asked questions
-
How many hospitalized incident cases of HER2+/HR+ breast cancer were seen in the 8MM in 2023?
In 2023, there were 107,352 hospitalized incident cases of HER2+/HR+ breast cancer in the 8MM.
-
What will be the growth rate of the HER2+/HR+ breast cancer market?
The hospitalized incident cases of HER2+/HR+ breast cancer will register an AGR of more than 1% during 2023-2033.
-
Which was the leading region in the HER2+/HR+ breast cancer market in 2023?
In 2023, Urban China was the leading region in the HER2+/HR+ breast cancer market.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.